Last updated: May 28, 2026
Brevibloc (Esmolol) Suppliers: Who Manufactures, Supplies, and Supplies API for US and EU Markets
Executive summary: Brevibloc is marketed in the US as esmolol hydrochloride injection. The supply chain is split between (1) manufacturing of the drug product for the labeled presentation(s) and (2) supply of esmolol HCl (or intermediates) to those drug-product manufacturers. Public sourcing for Brevibloc changes by labeler, strength, and packaging, so supplier identification must be tied to the specific NDC(s) and current FDA labeling/manufacturer entries.
Actionable bottom line: To identify the correct “suppliers,” you map from FDA NDC labeler/manufacturer for each Brevibloc strength and dosage form to the listed manufacturing facilities and any contract-manufacturing footprints reflected in FDA submissions and labeling. For any API sourcing claims, you must tie to controlled substance of supply chain evidence (DMF, inspectional history, or explicit labeling/manufacturer disclosure).
No supplier roster can be produced from the information provided in the prompt alone.
Who supplies Brevibloc esmolol injection in the US?
Direct answer: Brevibloc supply in the US is determined by the FDA drug product “labeler” and listed manufacturer(s) for each Brevibloc NDC and strength. Those entries control who “supplies” the product for regulatory and commercial purposes, not generic industry lore.
Which NDCs define the current Brevibloc labeler and manufacturer
- Brevibloc’s supplier list is NDC-specific.
- Each NDC includes: labeler name, strength, dosage form, and often manufacturer contact or site in FDA labeling/NDC records.
What “supplier” means commercially
For procurement and distribution, “supplier” can mean:
- Drug-product manufacturer (site making finished sterile injection)
- Labeler/marketing authorization holder (responsible entity on the label)
- Distributor/wholesaler (logistics, not manufacturing)
- API supplier (esmolol HCl, usually through DMF-backed supply chains)
Without the NDC(s) and labeled strengths in scope, a correct supplier mapping cannot be completed.
What are the API suppliers for esmolol hydrochloride used in Brevibloc?
Direct answer: API suppliers are reflected through DMF-linked commercial supply and inspectional/filing history, not through the consumer-level “Brevibloc” brand listing.
How to identify esmolol API suppliers
- Tie Brevibloc drug product to its commercial manufacturing route and any DMF references in FDA submissions.
- Cross-check whether the drug product is manufactured from esmolol HCl API supplied by specific API sites or synthesized in-house.
Why brand-level supplier names are not reliable for API
- Finished-dose manufacturers often change API sources.
- The brand labeler can remain constant while API suppliers shift due to cost, quality agreements, and supply continuity.
With no API-level evidence (DMF holders, filing cross-references, or inspection outcomes tied to Brevibloc), no accurate API supplier list can be provided.
Which companies manufacture Brevibloc sterile injection drug product?
Direct answer: The drug product manufacturer is the entity listed for the finished dosage form manufacturing in FDA labeling or NDC records for each Brevibloc NDC.
Sterile manufacturing constraints narrow the supplier set
For an IV short-acting beta-blocker injection:
- Manufacturing must meet sterile processing requirements (terminal sterilization or aseptic processing depending on the product specification).
- Supply is typically concentrated among a small set of parenteral sterile contract manufacturers.
What to check on the bottle/label and FDA record
- Labeled manufacturer or distributor name
- Sterile manufacturing facility identifier if listed
- NDC-specific labeler/manufacturer
No NDC-specific label data is provided in the prompt, so a company list cannot be validated.
How does Brevibloc supply chain work: labeler vs distributor vs manufacturing site?
Direct answer: In most regulated markets:
- The labeler/marketing entity is responsible for product release and labeling compliance.
- The manufacturer of record is the entity operating the finished-dose manufacturing site.
- Distributors/wholesalers move product but do not usually carry the manufacturing responsibility.
Procurement implication
- If you need a true supplier for continuity-of-supply or quality agreements, you need the finished-dose manufacturing site identifier, not only the distributor.
What procurement risks exist for Brevibloc supply and availability?
Direct answer: The primary procurement risk is loss of continuity in sterile injectable manufacturing capacity, which drives:
- Allocation or lead-time increases
- Temporary substitution via alternate NDCs if manufacturers switch
Where supply risk shows up
- FDA shortages list (if applicable for a given strength/NDC)
- Distributor allocation behaviors
- Lead-time changes tied to specific NDCs
No shortage/availability context or NDC range is provided here, so specific risk events cannot be tied to Brevibloc.
How do shortages and manufacturing changes affect Brevibloc suppliers by NDC?
Direct answer: When manufacturers change, it is usually per NDC/strength:
- A brand name remains constant while labeler/manufacturer entries change.
- Procurement must track the NDC, not the brand.
What to monitor
- NDC record updates
- Lot release notes in distribution channels
- FDA shortage notifications by dosage form/strength
No NDC list is available in the prompt.
What is the Orange Book status of Brevibloc, and how does that impact supplier selection?
Direct answer: Brand biologics and drugs with exclusivities can affect generic and biosimilar entry, but “supplier selection” is dominated by manufacturing and regulatory listing for the finished product, not exclusivity.
Key link
- Orange Book lists can help identify reference products and related approved ANDAs.
- That still does not enumerate API suppliers.
No Orange Book listing details can be extracted from the provided prompt.
How does Brevibloc compare with alternative esmolol products for supplier options?
Direct answer: Alternative esmolol products may have different manufacturers, which can expand procurement options, but this requires a specific competitor set (product name, strength, NDCs).
No competitor set is provided, so no comparison can be made.
Key Takeaways
- “Brevibloc suppliers” must be defined at the NDC level to identify the labeler and finished-dose manufacturer.
- API supplier identification requires DMF-backed or submission-linked evidence and is not reliably inferable from the brand name alone.
- Without NDC(s) and labeled strength(s) in scope, a validated supplier roster cannot be produced.
FAQs
- Which Brevibloc NDCs should procurement track to identify the true manufacturing supplier?
- How can a buyer distinguish the labeler from the drug-product manufacturer on Brevibloc packaging?
- Do Brevibloc and generic esmolol share the same API supplier, or can sources change over time?
- What documentation supports qualification of Brevibloc supply for sterile injectable procurement?
- How do FDA shortage notifications by strength and dosage form affect Brevibloc sourcing?
References
- FDA. Drug product NDC Directory (labeler/manufacturer entries).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. Drug Shortages (search by active ingredient/dosage form, if applicable).
